AUTHORS
Jowon Laura Kim, MD, Amar Harry Kelkar, MD, MPH2, Susan Parsons, MD, MRP3, Alison Moskowitz, MD4, Kishan Patel, MD5, Adrienne N. Nedved, PharmD, MPA6, Arushi Khurana, MBBS7, Jose C Villasboas, MD8, Jonas Paludo, MD9, Jithma Abeykoon, MD10, Yun Kyoung Tiger, MD, PhD11, Paul J. Hampel, MD12, Yucai Wang, MD, PhD13, Yi Lin Jr, MD, PhD14, Nora Bennani, MD15, Luis Porrata, MD16, Gita Thanarajasingam, MD17, Carrie Thompson, MD18, Patrick Johnston, MD, PhD19, Ivana Micallef, MD20, Thomas M. Habermann, MD21, Thomas Witzig, MD22, Philippe Armand, MD23, Stephen Maxted Ansell, MD, PhD24, Urshila Durani, MD, MPH25
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Tufts Medical Center, Boston, Massachusetts, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Recent trials have established N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) and BrECADD (brentuximab vedotin (BV), etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) as parallel standards in advanced-stage classic Hodgkin lymphoma (cHL). However, the comparative health economic value of these regimens is unknown, as differences in drug-acquisition costs, long-term disease control, salvage pathways, and survivorship may substantially influence cost-effectiveness over a lifetime horizon. Herein, we compared the cost-effectiveness of N-AVD and BrECADD from a US payer perspective.
Methods: We developed a five-state transition Markov model with monthly cycles and a lifetime horizon of 70 years (y, 840 cycles, median age of model 30y). Health states included: progression-free after first-line therapy (PF1), salvage therapy +/- autologous stem cell transplant (ASCT) for first progression (PD1; 3-month tunnel state), progression-free after salvage and ASCT (PF2), second progression (PD2), and death. In the base case, patients who relapsed after N-AVD were assumed to receive BV-ICE (BV, ifosfamide, carboplatin, etoposide) salvage, while patients who relapsed after BrECADD were assumed to receive Pembro-GVD (pembrolizumab, gemcitabine, vinorelbine, doxorubicin) salvage. Transition probabilities were derived from digitized and extrapolated Kaplan Meier curves from S1826 (Herrera et al. NEJM 2024), HD21 (Borchmann et al. Lancet 2024), BV-ICE (Lynch et al. Lancet Haem 2021), and Pembro-GVD (Moskowitz et al. JCO 2021) trials, and overall survival data from a real-world cohort of multiply relapsed cHL following ASCT and novel agent exposure (Voorhees et al. Blood Cancer J 2025).
Costs were derived from Centers for Medicare & Medicaid Services fee schedules and expressed in 2026 US dollars. Utilities were estimated for health states using previously reported measurements in cHL, prioritizing US/UK-based measurements (PF1: 0.783 during N-AVD, 0.753 during BrECADD, 0.91 within 5y post-treatment, and 0.95 thereafter; PD1: 0.43; PF2: 0.879; PD2: 0.673; Death: 0). Costs and quality-adjusted life years (QALYs) were discounted at 3% annually.
To explore uncertainty in model assumptions, we performed one-way sensitivity analyses (OWSA), two-way sensitivity analyses (TWSA), and probabilistic sensitivity analysis (PSA; 10,000 Monte Carlo simulations), varying global model parameters, frontline efficacy, costs, utilities, and PD1 transition probabilities. Outcomes included incremental cost-effectiveness ratio (ICER) and incremental net monetary benefit (INMB) at a willingness-to-pay (WTP) threshold of $150,000/QALY.
Results: In the base case, BrECADD increased discounted QALYs by 0.50 and life-years by 0.36 at an incremental cost of $39,307, yielding an ICER of $79,298/QALY and an INMB of $35,046 at a WTP of $150,000/QALY.
In PSA, the mean incremental cost for BrECADD was $36,872, and the mean incremental QALY gain was 0.477, with a ratio-of-means ICER of $77,266/QALY. The probability that BrECADD was cost-effective was 56.4% at a WTP threshold of $100,000/QALY, 66.8% at a WTP of $150,000/QALY, and 73.5% at a WTP of $200,000/QALY.
In OWSA, the base case conclusion was most sensitive to varying N-AVD 5y PFS (crossing WTP threshold at ≥90.2%), long-term PF1 utility (threshold ≤0.785), N-AVD cost per cycle (threshold ≤71% of base case), BrECADD cost per cycle (threshold ≥119% of base case), and the time horizon (threshold ≤26y). TWSA confirmed that BrECADD remained the preferred strategy across most plausible combinations of efficacy, cost, and follow-up duration, becoming not cost-effective only when these thresholds were crossed.
Scenario analyses showed that the ICER rose to $176,019/QALY when both frontline strategies received Pembro-GVD as second-line therapy, and to $111,123/QALY when both received BV-ICE.
Conclusion: From a US payer perspective, BrECADD followed by Pembro-GVD upon relapse, is likely to provide acceptable economic value compared with N-AVD followed by BV-ICE for advanced-stage cHL, at a WTP of $150,000/QALY. Cost-effectiveness was driven primarily by differences in frontline disease control and remained robust across most plausible parameter estimates, although most sensitive to assumptions regarding frontline disease control, drug costs, salvage therapy, and time horizon.
DISCLOSURES
Jowon Laura Kim, MD: No relevant conflicts of interest to declare.